Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is studying how well carboplatin, paclitaxel, and bevacizumab
work when given with or without everolimus in treating patients with malignant melanoma that
has spread from where it started to other places in the body. Drugs used in chemotherapy,
such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as
bevacizumab, may block the ability of tumor cells to grow and spread. Everolimus may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking
blood flow to the tumor. It is not yet known whether combination chemotherapy given together
with bevacizumab is more effective with or without everolimus in treating patients with
metastatic melanoma.